Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT04569643
Other study ID # 2207
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date December 1, 2020
Est. completion date August 31, 2022

Study information

Verified date August 2020
Source I.M. Sechenov First Moscow State Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Patients from 60 to 75 years old diagnosed with cerebral small vessel disease with no history of symptomatic stroke, brain tumor, traumatic brain injury, seizures and neurodegenerative or mental disorder will undergo overnight leg actigraphy and cardiorespiratory monitoring. Those of them with apnea/hypopnea index under 5 will be enrolled. Brain MRI and cognitive assessment will be performed at baseline and in 1-year follow-up, sleep quality will be assessed at baseline with self-reported questionnaires. Progression of cerebral small vessel disease markers and cognitive dysfunction will be compared between patients with high periodic limb movement index (the number of periodic limb movement ≥ 15 per hour of sleep) and controls (periodic limb movement index < 15/h).


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 76
Est. completion date August 31, 2022
Est. primary completion date April 30, 2022
Accepts healthy volunteers No
Gender All
Age group 60 Years to 75 Years
Eligibility Inclusion Criteria: - Diagnosis of a cerebral small vessel disease - assessed by MRI. - Ability to follow the procedures of the study, fluent Russian language - assessed by self-report. Exclusion Criteria: - History of symptomatic stroke, brain tumor or traumatic brain injury - assessed by self-report and clinical history. - History of severe psychiatric comorbidities other than anxiety and depression, substance use disorder - assessed by self-report and clinical history. - Significant visual loss (leading to difficulties with performing cognitive tasks) - assessed by self-report and clinical history. - Presence of dementia - assessed by history and clinical examination. - Movement disorders (e.g. tremor, dystonia etc.) leading to lower velocity of performing cognitive tasks against the clock - assessed by clinical examination. - Obstructive sleep apnea syndrome - according to the criteria of International classification of sleep disorders III. - Restless legs syndrome - according to the criteria of the International restless legs syndrome study group. - Current intake of neuroleptics, benzodiazepines, selective serotonin reuptake inhibitors - assessed by self-report and clinical history.

Study Design


Intervention

Diagnostic Test:
Actigraphy
Participants will undergo overnight leg actigraphy at baseline. Leg movements will be recorded bilaterally by actigraphic method with two ankle-worn recorders.
Cardiorespiratory monitoring
All participants will be scanned for presence of sleep-related breathing disorders with a portable monitoring device at baseline. The compact screening device will be attached to the patient's wrist during the night sleep.
Neuroimaging
All subjects will undergo brain MRI scanning at baseline and in 1-year follow-up. The imaging protocol will include axial T1, T2, T2*, FLAIR and diffusion-weighted imaging scans that will be made on a 3-Tesla scanner.
Other:
Assessment of cognitive function
Assessment will take place at weeks 0 (baseline) and 52 (1 year follow-up). The neuropsychological protocol will be consist of Montreal Cognitive Assessment (MoCA), 12-word Verbal Memory Test, Benton Visual Retention Test, Frontal Assessment Battery, Trail Making Test (parts A and B), phonetic (as a part of the MoCA) and semantic verbal fluency assessment, Symbol Digit Modalities Test.
Sleep quality and mood questionnaires
Self-reporting scales and questionnaires will be used at baseline to assess sleep quality, daytime functioning and mood. The protocol includes the Pittsburgh Sleep Quality Index, the Epworth Sleepiness Scale, the Geriatric Depression Scale.

Locations

Country Name City State
Russian Federation I.M. Sechenov First Moscow State Medical University (Sechenov University) Moscow

Sponsors (1)

Lead Sponsor Collaborator
I.M. Sechenov First Moscow State Medical University

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary White matter hyperintensities volume change All the images will be processed with online software pipeline to make an automated volumetric measurement of white matter hyperintensities. The volume of the white matter lesion will be calculated separately for the periventricular, juxtacortical, infratentorial and deep white matter areas as well as total volume of the lesion. Baseline volumes will be subtracted from follow-up volumes to obtain absolute white matter hyperintensities volume change. 1 year
Primary Degree of Cognitive Decline The scores of cognitive tests (Montreal Cognitive Assessment (MoCA), 12-word Verbal Memory Test, Benton Visual Retention Test, Frontal Assessment Battery, Trail Making Test (parts A and B), phonetic and semantic verbal fluency assessment, Symbol Digit Modalities Test) at baseline will be subtracted from the corresponding baseline scores. The obtained difference reflects the degree of cognitive decline in 1 year. 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05273125 - MOBility Disorders Assessment in Patients With Mild COGnitive Disorders
Active, not recruiting NCT04049695 - Improving Cognition After Cancer N/A
Completed NCT05912374 - Adapting a Behavioral Intervention to Accommodate Cognitive Dysfunction in People Who Inject Drugs N/A
Recruiting NCT03977350 - Association Between qEEG Measure and Post-Operative Cognitive Dysfunction (POCD) and Postoperative Delirium (POD)
Not yet recruiting NCT06027632 - Remotely Supervised Computerized Cognitive Stimulation to Reduce Post-chemotherapy Cognitive Difficulties in Patients Treated for Localized Breast Cancer N/A
Terminated NCT00754052 - Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17 Phase 3
Completed NCT00719628 - Depth of Anaesthesia and Cognitive Dysfunction N/A
Terminated NCT00754013 - Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10 Phase 3
Recruiting NCT05014399 - Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy
Completed NCT04966455 - Effect of Raisins on Cognitive Function in Healthy Older Adults Phase 3
Recruiting NCT05372159 - Vanderbilt Memory and Aging Project
Completed NCT03243279 - BRS and Outcomes in Cardiothoracic Surgery
Completed NCT04093882 - The Relevance of the Blood-brain Barrier to Cognitive Dysfunction and Alzheimer's Disease
Recruiting NCT05732285 - A Pilot Randomized Controlled Trial: CoINTEGRATE N/A
Completed NCT06059768 - Urdu Translation and Psychometric Analysis of Lawton IADLS.
Completed NCT04562662 - Evaluation of mediVR-KAGURA Guided Therapy N/A
Completed NCT04624529 - Validity and Reliability of a Self-evaluation Tool for Cognitive Deficits in the Acute Stage After Stroke
Not yet recruiting NCT04079075 - Multiple Interventions to Prevent Cognitive Decline N/A
Active, not recruiting NCT04638101 - Building the Path to Resilience in Preterm Infants: Mindfulness-based Intervention N/A
Active, not recruiting NCT04556305 - Lifestyle Physical Activity and Cognitive Training Interventions N/A